Bizarre Patents
A forehead support apparatus for resting a standing users forehead against a wall above a bathroom commode or urinal or beneath a showerhead.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8202869 | Method of treating an anxiety disorder Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosi... | 06/19/2012 |
| 7763625 | Agents for treating migraine A method for treating migraine comprising administering, as an active ingredient, a xanthine derivative represented by the following formula or a pharmaceutically acceptable salt thereof. ... | 07/27/2010 |
| 7759355 | Adenosine A2A receptor antagonists for treating restless legs syndrome or nocturnal myoclonus The present invention provides methods of treating restless legs syndrome or related disorders, comprising administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof. More preferably the adenosine A | 07/20/2010 |
| 5703085 | Xanthine derivatives The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R1, R2, and R3 independently represent hydrogen, lower alkyl, low... | 12/30/1997 |
| 5698560 | Imidazoquinazoline derivatives The present invention relates to imidazoquinazoline derivatives represented by formula (I): ##STR1## wherein R1 represents hydrogen, substituted or unsubstituted lower alkyl, cycloalkyl, lower alkenyl, substituted or unsubstituted aralkyl,... | 12/16/1997 |
| 5670498 | 8-substituted styryl xanthine derivatives Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R1, R2, and R3 independently represent hydrogen or lower alkyl; Q1, Q2, and Q3 independen... | 09/23/1997 |
| 5661147 | Imidazoquinazoline derivatives The present invention relates to imidazoquinazoline derivatives represented by the general formula (I): ##STR1## or pharmacologically acceptable salts thereof. The compounds of the present invention have strong and selective cGMP-specific PDE inhibit... | 08/26/1997 |
| 5658917 | Isoquinolines having adenosine uptake inhibitor activity The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ... | 08/19/1997 |
| 5648353 | Quinazolines and phthalazines having adenosine uptake inhibitor activity The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ... | 07/15/1997 |
| 5624926 | Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ... | 04/29/1997 |
| 5605900 | Benzotriazines having adenosine uptake inhibitor activity The present invention relates to an adenosine uptake inhibitor and an agent for the myocardium protection or the prevention or treatment of inflammatory edema, comprising a 1,2,3,4-tetrahydro-2,4-dioxoquinazoline derivative represented by formula (I): ... | 02/25/1997 |
| 5342841 | Xanthine derivatives A xanthine derivative of the formula (I): ##STR1## wherein R1 and R2 are the same or different and are substituted or unsubstituted alicyclic alkyl; m1 and m2 are the same or different and represent an integer of 0 to 2; and Q r... | 08/30/1994 |
| 5142096 | 2,4-dihydroxy-3,5,6-trimethylbenzoic acid compounds KS-506a, KS-506x and KS-506g having an activity to inhibit cyclic nucleotide phosphodiesterase and KS-506m and KS-506h having an activity to inhibit histamine release are produced by culturing a microorganism belonging to the genus Mortierella.... | 08/25/1992 |
| 4990693 | Novel substances KS-504a, KS-504b, KS-504d and KS-504e and process for their preparation Novel physiologically active substances KS-504a, KS-504b and KS-504d having a vasodilative activity and a novel physiologically active substance KS-504e having an activity to inhibit histamine secretion are produced by culturing a microorganism of the gen... | 02/05/1991 |
| 4962125 | Novel substance KS-619-1, preparation process and pharmaceutical composition A novel physiologically active substance KS-619-1 having a vasodilative activity is produced by culturing Streptomyces californicus ATCC 3312.... | 10/09/1990 |
| 4912132 | Novel substances KS-504a, KS-504b, KS-504d and KS-504e and process for their preparation Novel physiologically active substances KS-504a, KS-504b and KS-504d having a vasodilative activity and a novel physiologically active substance KS-504e having an activity to inhibit histamine secretion are produced by culturing a microorganism of the gen... | 03/27/1990 |
| 4868159 | Novel substances KS-501 and KS-502 and process for their preparation Novel physiologically active substances KS-501 and KS-502 having inhibitory activity on serotonin release from platelets and/or platelet aggregation are produced by culturing a microorganism of the genus Sporothrix.... | 09/19/1989 |
| 4692310 | Substance K-259-2 and a process for producing the same A new substance K-259-2 having a molecular formula of C21 H18 O7, a molecular weight of 382 and an elemental analysis (%) of H: 4.50, C: 65.53 and N: 0. This substance is of interest in providing a new vasodilating agent i... | 09/08/1987 |
| 4683220 | Novel physiologically active substances K-26, a process for preparation thereof and a pharmaceutical composition containing the same Disclosed is a novel physiologically active substance, K-26, a process for preparation thereof and a pharmaceutical composition containing the same. The composition of matter, K-26, is useful as a hypotensive agent.... | 07/28/1987 |
| 4657916 | Quinoline-N-oxide derivative and pharmaceutical composition A quinoline-N-oxide derivative represented by the formula: ##STR1## wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R | 04/14/1987 |
| 4618613 | Preventive and healing composition for diseases due to lipoxygenase metabolic products A preventive and healing composition for diseases due to lipoxygenase metabolic products, which comprises an effective amount of a compound represented by the formula: ##STR1## wherein R is an alkyl group having 1 to 15 carbon atoms and at least one ... | 10/21/1986 |
| 4555402 | Physiologically active substance K-252, process for producing same and pharmaceutical composition containing same A novel physiologically active substance K-252 having an antiallergic action is produced by culturing a microorganism of the genus Nocardiopsis.... | 11/26/1985 |
| 4522812 | Novel physiologically active substance K-4, a process for preparation thereof and a pharmaceutical composition containing the same Disclosed is a novel physiologically active substance K-4 which has a hypotensive activity, a process production thereof and a pharmaceutical composition containing the same.... | 06/11/1985 |
